Drug target identification with the reasoning left visible

Axira target identification assembles evidence for candidate targets across biological pathways, omics layers, literature, and clinical signals, then ranks them with the contribution of each evidence type made explicit. The ranking is an argument, presented as one.

Where the evidence is thin, the system says so rather than smoothing the gap. A target ranked fourth with strong evidence is more useful than a target ranked first on a score nobody can decompose.

Evidence enters through the governed data layer with provenance recorded. Scoring runs through validated inference pipelines, and explainability is a required output rather than an optional view, so every position in the ranking can be decomposed into the evidence that produced it.

Model orchestration stays vendor agnostic, so the reasoning behind a target decision does not become dependent on one provider's model.

The FDA draft guidance on AI in regulatory decision-making explicitly does not extend to drug discovery, which means target identification sits outside that framework. That makes the discipline voluntary, and it is worth keeping anyway, because a target that advances will eventually carry its evidence into phases where the framework does apply.

Building the traceability at the discovery stage costs less than reconstructing it later.